ProShare Advisors LLC lessened its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 7.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 21,072 shares of the biotechnology company’s stock after selling 1,668 shares during the period. ProShare Advisors LLC owned 0.06% of Repligen Corporation worth $873,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new position in shares of Repligen Corporation during the 1st quarter worth $103,000. Victory Capital Management Inc. raised its holdings in shares of Repligen Corporation by 76.6% during the 1st quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 1,475 shares during the period. Oppenheimer Asset Management Inc. purchased a new position in shares of Repligen Corporation during the 2nd quarter worth $123,000. JPMorgan Chase & Co. raised its holdings in shares of Repligen Corporation by 31.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 908 shares during the period. Finally, US Bancorp DE raised its holdings in shares of Repligen Corporation by 1.2% during the 2nd quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock worth $191,000 after acquiring an additional 54 shares during the period. Institutional investors and hedge funds own 97.91% of the company’s stock.

Shares of Repligen Corporation (NASDAQ RGEN) opened at 38.32 on Friday. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The company’s 50 day moving average price is $42.29 and its 200-day moving average price is $39.00. The firm has a market capitalization of $1.43 billion, a P/E ratio of 74.99 and a beta of 1.21.

Repligen Corporation (NASDAQ:RGEN) last released its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The firm had revenue of $32.40 million for the quarter, compared to the consensus estimate of $31.72 million. During the same period in the prior year, the business posted $0.16 earnings per share. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. On average, equities analysts predict that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.

RGEN has been the topic of several analyst reports. Janney Montgomery Scott lifted their price target on Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. TheStreet raised Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Saturday, August 12th. BidaskClub raised Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $40.00 price objective (up from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $44.60.

WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/proshare-advisors-llc-has-873000-stake-in-repligen-corporation-rgen/1600451.html.

Repligen Corporation Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.